Although joining a startup company always brings a certain degree of risk–especially those who are committed to developing new products in the highly regulated medical device field–more and more experienced medical technology executives have learned from them to stabilize, The perfect character jumps into the dark waters of the entrepreneurial world.
The newest adventurer is Jeff Cambra, who has held top positions in companies such as Zimmer Biomet and Medtronic, and now provides expertise to serve as the CEO of SpinaFX.
The Canadian company only recently launched its first product, Triojection, an image-guided therapy for back pain caused by a herniated disc. During the operation, doctors use fluoroscopy to guide needles into the affected discs, where they deliver a dose of oxygenated compounds designed to reduce inflammation and pain over time.
The system is designed to provide a minimally invasive alternative to traditional surgical procedures, making it easier for surgeons to perform operations and allowing patients to recover faster.
SpinaFX restored the technology from the now-defunct Minimus Spine, which received the CE mark of Triojection in 2014. Since then, with more stringent regulatory guidelines in place, SpinaFX is now seeking new European approvals for the system and recognition by other agencies in the United States, Canada and other regions.
Related: Medtronic’s Intellis Spinal Cord Stimulator Algorithm Can Relieve Back Pain in One Year
Cambra will help lead this trend. He joined SpinaFX just after working at Zimmer Biomet for eight months, where he served as the vice president responsible for product management of the equipment manufacturer’s global reconstruction business.
Prior to this, he worked at Medtronic for more than ten years. During that time, he rose from marketing director to senior director of business development and strategy, and finally became the vice president and general manager of the interventional therapy department of this medical technology giant. In his last position at Medtronic, Cambra was responsible for overseeing the development of new technologies and the formation of partnerships and acquisitions to promote the company’s work in vertebral augmentation and oncology.
Before moving towards medical technology, Cambra worked in the pharmaceutical field for another ten years. Until 2009, he held several positions at Wyeth Pharmaceuticals, the manufacturer of Robitussin and Advil that Pfizer acquired in 2009.
Related: Zimmer Biomet hires former Medtronic executive to lead new spinal and dental spin-off
“I am very happy and honored to join SpinaFX to bring its novel back pain therapy to the market. With my passion for the interventional field, I continue to evaluate and monitor a variety of promising technologies-more than ten years ago, I recognized SpinaFX The breakthrough potential of technology,” he said in a statement. “SpinaFX is a great opportunity to use my experience in the medical device field to create value for our patients, customers and shareholders.”
In recent months, Cambra has not been the only Medtronic veteran on a new path. Earlier this year, Vafa Jamali, who was previously Medtronic’s senior vice president and president of the respiratory, gastrointestinal and informatics divisions, was appointed as the CEO of the spin-off company consisting of Zimmer Biomet’s dental and spine businesses.